Lungs - Idiopathic Pulmonary Fibrosis (IPF)
From Pipe Line - Fibrosis
A specific form of lung fibrosis is Idiopathic pulmonary fibrosis (IPF), which is a chronic and ultimately fatal disease, where tissue deep in the lungs becomes scarred, over time, resulting in a progressive decline in lung function and shortness of breath. There is currently no cure for IPF with most people living only three to five years after diagnosis. The rate at which the disease progresses is highly variable, with some patients remaining stable for several years while others may deteriorate rapidly, 50% of patients die within two to three years of diagnosis.
Product Details
IPF is rare, but still affects over 135, 000 people in the United States (US), with about 48,000 new cases being diagnosed annually. In the US 40,000 people die each year from IPF; the same mortality as breast cancer. In addition IPF affects about 100,000 people in Europe and 5,000 people in Australia. Because this condition affects less than 200,000 patients within the United States or Europe, any products or drugs addressing this indication are referred to as orphan drugs.
In 2017, AdAlta applied for and achieved what’s known as “Orphan Drug Designation” with the United States Food and Drug Administration (FDA.) Access to the Orphan Drug Designation scheme means that AdAlta gets increased access to the FDA, new drug application fee waivers, a potentially faster route to market and an additional seven years of exclusivity once the drug is on market.
Other resources
For an up-to-date summary on our recent progress, view our ASX announcements, investor presentations and scientific publications.
Respiratory Physician at The Alfred hospital, Dr Glen Westall spoke at AdAlta’s inaugural fibrosis investor briefing, where he provided an overview of IPF and currently available treatments. The full-length presentation is available on AdAlta’s website as well as a video highlight of the day.
Customer reviews
No reviews were found for Lungs - Idiopathic Pulmonary Fibrosis (IPF). Be the first to review!